Advanced Oncotherapy PLC (AVO) Rating Reiterated by Beaufort Securities
Advanced Oncotherapy PLC (LON:AVO)‘s stock had its “speculative buy” rating reaffirmed by Beaufort Securities in a research report issued on Monday.
Shares of Advanced Oncotherapy PLC (LON:AVO) opened at 61.10 on Monday. The stock’s market cap is GBX 34.66 million. Advanced Oncotherapy PLC has a one year low of GBX 61.00 and a one year high of GBX 217.25. The stock’s 50 day moving average is GBX 99.38 and its 200-day moving average is GBX 126.12.
WARNING: “Advanced Oncotherapy PLC (AVO) Rating Reiterated by Beaufort Securities” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and reposted in violation of U.S. and international copyright laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2016/11/30/advanced-oncotherapy-plc-avo-rating-reiterated-by-beaufort-securities-3.html.
Advanced Oncotherapy PLC Company Profile
Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device and management of healthcare related property.
Receive News & Stock Ratings for Advanced Oncotherapy PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy PLC and related stocks with our FREE daily email newsletter.